Investors interested in stocks from the Chemical - Specialty sector have probably already heard of H. B. Fuller (FUL) and PPG Industries (PPG).
H.B. Fuller Company (FUL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q2
while the forward P/E of 13.06 suggests potential value, the high debt-to-equity ratio of 1.00 and inconsistent free cash flow margins, which fluctuated between -10.9% and 8.8% recently, warrant a cautious wait-and-see approach.
H.B. Fuller Company (FUL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
H.B. Fuller Company (FUL) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 24, 2026 | $1.41vs $1.37+2.9% | $950Mvs $925M+2.8% |
| Q2 2026 | Mar 25, 2026 | $0.57vs $0.56+2.7% | $771Mvs $785M-1.8% |
| Q1 2026 | Jan 14, 2026 | $1.28vs $1.24+3.2% | $895Mvs $903M-0.9% |
| Q4 2025 | Sep 24, 2025 | $1.26vs $1.24+1.6% | $892Mvs $896M-0.4% |
Recent stock market news and headlines for H.B. Fuller Company (FUL)
Investors interested in stocks from the Chemical - Specialty sector have probably already heard of H. B. Fuller (FUL) and PPG Industries (PPG).
FUL flags stronger pricing, higher profit guidance and a proposed AMS deal aimed at expanding its medical adhesives platform and boosting margins.
H.B. Fuller is rated a "buy" with a conservative $80/share price target, reflecting improved fundamentals and recent M&A. FUL's recent results validate earnings recovery: near-6% revenue growth, ~20% AEPS improvement, double-digit EBITDA gains, and record operating cash flow. The AMS acquisition is expected to drive margin expansion, higher-quality revenue, and meaningful revenue and cost synergies, supporting long-term profitability.

H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript

CLEVELAND--(BUSINESS WIRE)--Ancora Holdings Group, LLC (collectively with its affiliates, “Ancora” or “we”) today released the below statement regarding H.B. Fuller Company (NYSE: FUL) (“H.B. Fuller” or the “Company”) and Advanced Medical Solutions Group plc (“AMS”). Previously, Ancora issued a letter to H.B. Fuller's Board of Directors (the “Board”) regarding its contemplated acquisition of AMS. Fredrick D. DiSanto, Chairman and Chief Executive Officer of Ancora, and James Chadwick, President.

Key metrics vs top competitors for H.B. Fuller Company (FUL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $57.57 | $3.1B | 20.93 | -2.67% | 4.37% | 7.93% | 1.58% | |
| $81.83 | $20.9B | -56.05 | -5.17% | 7.78% | 5.88% | — | |
| $108.28 | $13.87B | 20.24 | 0.51% | 8.63% | 21.79% | — | |
| $164.35 | $12.64B | 18.72 | 1.14% | 7.66% | 30.81% | — | |
| $168.11 | $5.38B | 35.39 | 8.75% | 14.95% | 12.38% | — | |
| $342.26 | $84.41B | 33.33 | 2.06% | 10.86% | 58.23% | — |
H.B. Fuller Company (FUL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
H.B. Fuller Company (FUL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 26, 2026·SEC
Jun 25, 2026·SEC
Apr 17, 2026·SEC
Jan 22, 2026·SEC
Get notified when FUL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
H.B. Fuller Company (FUL) stock FAQ — growth, dividends, profitability & financials explained
H.B. Fuller Company (FUL) reported $3.51B in revenue for fiscal year 2025. This represents a 175% increase from $1.28B in 1996.
H.B. Fuller Company (FUL) saw revenue decline by 2.7% over the past year.
Yes, H.B. Fuller Company (FUL) is profitable, generating $185.7M in net income for fiscal year 2025 (4.4% net margin).
Yes, H.B. Fuller Company (FUL) pays a dividend with a yield of 1.58%. This makes it attractive for income-focused investors.
H.B. Fuller Company (FUL) has a return on equity (ROE) of 7.9%. This is below average, suggesting room for improvement.
H.B. Fuller Company (FUL) generated $140.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.